Keywords
atherosclerosis
asthma
Categories
How to Cite
Abstract
Chitinase-3-like protein 1 (CHI3L1) is a secreted glycoprotein that is implicated in a wide array of physiological processes, including inflammatory responses, tissue remodeling, apoptosis, and immune regulation. This protein is implicated in the pathogenesis of numerous systemic diseases, including those affecting the respiratory system (e.g., asthma, pulmonary fibrosis), the cardiovascular system (e.g., atherosclerosis, hypertension), the nervous system (e.g., Alzheimer’s disease, neuroinflammation), the digestive system (e.g., hepatic fibrosis), the urinary system (e.g., renal injury), the endocrine system (e.g., diabetes mellitus), the rheumatological and immune systems (e.g., rheumatoid arthritis), the musculoskeletal system (e.g., osteoporosis), and the reproductive system (e.g., endometriosis). This review summarizes current understanding and recent advancements regarding the role of CHI3L1 in these systemic disorders. Advances in detection methodologies and a growing elucidation of its underlying mechanisms position CHI3L1 as a promising biomarker and therapeutic target, offering significant potential to advance early diagnosis, disease monitoring, and precision medicine for a diverse array of pathological conditions.
References
[1] Zhao T, Su Z, Li Y, Zhang X, You Q. Chi-tinase-3 like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5(1):201. Published 2020 Sep 14.
[2] Yu JE, Yeo IJ, Han SB, et al. Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer. Exp Mol Med. 2024;56(1):1-18.
[3] Liu D, Hu X, Ding X, Li M, Ding L. Inflam-matory Effects and Regulatory Mechanisms of Chitinase-3-like-1 in Multiple Human Body Systems: A Comprehensive Review. Int J Mol Sci. 2024;25(24):13437.
[4] Jankowska-Konsur A, Łyko M, Rubas K, Nowicka-Suszko D, Maj J, Szepietowski JC. Chitinase-3-like Protein 1 (YKL-40): A New Biomarker of Inflammation in Pyoderma Gangrenosum.[J]. Acta Derm Venereol. 2022 Feb 11;102: adv00646.
[5] Ge L, Wang Y, Liu Z, Du H, Zhao D. Chi-tinase 3-like 1 plays a pivotal role in airway response of RSV infection via regulating DC functional transition. Int Immunopharmacol. 2023 Nov;124(Pt A):110819.
[6] Knihtilä H, Kotaniemi-Syrjänen A, Pelkonen AS, Savinko T, Malmberg LP, Mäkelä MJ. Serum chitinase-like protein YKL-40 is linked to small airway function in children with asthmatic symptoms. Pediatr Allergy Immunol. 2019 Dec;30(8):803-809.
[7] Lee SY, Lee CM, Ma B, et al. Targeting Chi-tinase 1 and Chitinase 3-Like 1 as Novel Therapeutic Strategy of Pulmonary Fibro-sis. Front Pharmacol. 2022; 13:826471.
[8] Cao Y, Rudrakshala J, Williams R, et al. CRTH2 Mediates Profibrotic Macrophage Differentiation and Promotes Lung Fibro-sis. Am J Respir Cell Mol Biol. 2022;67(2):201-214.
[9] Sun X, Nakajima E, Norbrun C, et al. Chi-tinase 3 like 1 contributes to the develop-ment of pulmonary vascular remodeling in pulmonary hypertension. JCI Insight. 2022;7(18): e159578.
[10] Hong DE, Yu JE, Yoo SS, et al. CHI3L1 in-duces autophagy through the JNK pathway in lung cancer cells. Sci Rep. 2023;13(1):9964. Published 2023 Jun 20.
[11] Park KR, Yun HM, Yoo K, Ham YW, Han SB, Hong JT. Chitinase 3 like 1 suppresses the stability and activity of p53 to promote lung tumorigenesis. Cell Commun Signal. 2020;18(1):5. Published 2020 Mar 4.
[12] Yu JE, Yeo IJ, Son DJ, Yun J, Han SB, Hong JT. Anti-Chi3L1 antibody suppresses lung tumor growth and metastasis through inhibi-tion of M2 polarization. Mol Oncol. 2022;16(11):2214-2234.
[13] Ferrigno I., Verzellesi L., Ottone M., Bonacini M., Rossi A., Besutti G., Bonelli E., Colla R., Facciolongo N., Teopompi E., et al. CCL18, CHI3L1, ANG2, IL-6 systemic levels are as-sociated with the extent of lung damage and radiomic features in SARS-CoV-2 infection. Inflamm. Res. 2024; 73:515–530.
[14] Wen S.H., Cheng S.H., Xie S.B., Zhang H., Xie Z.H., Jiang W.H. Serum YKL-40 levels pre-dict endotypes and associate with postopera-tive recurrence in patients with chronic rhi-nosinusitis with nasal polyps. J. Asthma Al-lergy. 2021; 14:1295–1306.
[15] Zhang Y., Su X.L., Pan P.H., Hu C.P. The se-rum YKL-40 level is a potential biomarker for OSAHS: A systematic review and me-ta-analysis. Sleep Breath. 2020; 24:923–929.
[16] Huan W., Yandong L., Chao W., Sili Z., Jun B., Mingfang L., Yu C., Lefeng Q. YKL-40 ag-gravates early-stage atherosclerosis by in-hibiting macrophage apoptosis in an aven-dependent way. Front. Cell Dev. Biol. 2021; 9:752773.
[17] Liu Y, Hu W, Yang F, Zou S, Ren H, Zuo Y, Qu L. Chitinase-3-like Protein 1 Reduces the Stability of Atherosclerotic Plaque via Im-pairing Macrophagic Efferocytosis. J Cardi-ovasc Transl Res. 2025 Feb;18(1):3-16.
[18] Gulati R, Behfar A, Narula J, Kanwar A, Lerman A, Cooper L, Singh M. Acute myo-cardial infarction in young individuals. [J]. Mayo Clin Proc. 2020; 95:136–156.
[19] Schroder J, Jakobsen JC, Winkel P, et al. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease. [J]. J Am Heart Assoc. 2020;9(5): e014634.
[20] [20] LUO L Q, WANG Q G. Research pro-gress of YKL-40 in metabolic diseases and cardiovascular diseases [J]. Popular Science & Technology, 2022, 24(03): 86-90.
[21] GAO L H, QUAN H J, GUO X N, et al. Pre-dictive value of serum YKL-40 levels for major adverse cardiovascular events in pa-tients with ST-segment elevation myocardial infarction after percutaneous coronary in-tervention [J]. Chinese Journal of Microcir-culation, 2023, 33(04): 51-55.
[22] Stephan JK, Knerr T, Gu Z, Li H, Brittian KR, Dassanayake S, Singhal R, Nong Y, Jones SP, Wysoczynski M. Neutrophil-secreted CHI3L1 exacerbates cardiac dysfunction and inflammation after myocardial infarction. FASEB J. 2025 Mar 15;39(5): e70422.
[23] Xu T, Zheng X, Wang A, Guo Z, Zhang Y. Association of CHI3L1 gene variants with YKL-40 levels and hypertension incidence: A population-based nested case-control study in China. [J]. J Cell Mol Med. 2021;25(2):919-924.
[24] Xu S, Zhang G, Tan X, Zeng Y, Jiang H, Jiang Y, Wang X, Song Y, Fan H, Zhou Y. Plasma Olink Proteomics Reveals Novel Biomarkers for Prediction and Diagnosis in Dilated Car-diomyopathy with Heart Failure. J Proteome Res. 2024 Sep 6;23(9):4139-4150.
[25] Zeng X, Cheung SKK, Shi M, Or PMY, Li Z, Liu JYH, Ho WLH, Liu T, Lu K, Rudd JA, Wang Y, Chan AM. Astrocyte-specific knockout of YKL-40/Chi3l1 reduces Aβ burden and restores memory functions in 5xFAD mice. J Neuroinflammation. 2023 Dec 2;20(1):290.
[26] Mwale PF, Hsieh CT, Yen TL, et al. Chi-tinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pa-thologies with therapeutic implications. Mol Neurodegener. 2025;20(1):7.
[27] Jiang W, Zhu F, Xu H, Xu L, Li H, Yang X, et al. CHI3L1 signaling impairs hippocampal neurogenesis and cognitive function in au-toimmune-mediated neuroinflammation. Sci Adv. 2023;9(39): eadg8148.
[28] Ham HJ, Lee YS, Yun J, Son DJ, Lee HP, Han S-B, et al. K284–6111 alleviates memory impairment and neuroinflammation in Tg2576 mice by inhibition of Chi-tinase-3-like 1 regulating ERK-dependent PTX3 pathway. J Neuroinflammation. 2020; 17:1–16.
[29] Zhao T, Zeng J, Xu Y, et al. Chitinase-3 like-protein-1 promotes glioma progression via the NF-κB signaling pathway and tumor microenvironment reprogram-ming. Theranostics. 2022;12(16):6989-7008.
[30] Chen A, Jiang Y, Li Z, et al. Chitinase-3-like 1 protein complexes modulate macro-phage-mediated immune suppression in gli-oblastoma. J Clin Invest. 2021;131(16): e147552.
[31] Xu A, Luo Y, Tang Y, Yang F, Gao X, Qiao G, Zhu X, Zhou J. Chitinases as a potential di-agnostic and prognostic biomarker for amy-otrophic lateral sclerosis: a systematic re-view and meta-analysis. Neurol Sci. 2024 Jun;45(6):2489-2503.
[32] Yu W, Gui S, Peng L, Luo H, Xie J, Xiao J, Yilamu Y, Sun Y, Cai S, Cheng Z, Tao Z. STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial het-erogeneity and immune characteristics of glioblastoma. Dev Cell. 2025 Feb 7: S1534-5807(25)00034-6.
[33] Kui L, Kim AD, Onyuru J, Hoffman HM, Feldstein AE. BRP39 Regulates Neutrophil Recruitment in NLRP3 Inflam-masome-Induced Liver Inflammation. Cell Mol Gastroenterol Hepatol. 2024;17(3):481-497.
[34] Jin G, Guo N, Liu Y, Zhang L, Chen L, Dong T, Liu W, Zhang X, Jiang Y, Lv G, Zhao F, Liu W, Hei Z, Yang Y, Ou J. 5-aminolevulinate and CHIL3/CHI3L1 treatment amid ischemia aids liver metabo-lism and reduces ischemia-reperfusion injury. Theranostics. 2023 Aug 28;13(14):4802-4820.
[35] Li Y, Li C, Zhang L, Hu W, Luo H, Li J, Qiu S, Zhu S. Serum CHI3L1 as a diagnostic marker and risk factor for liver fibrosis in HBeAg-negative chronic hepatitis B. Am J Transl Res. 2022 Jun 15;14(6):4090-4096.
[36] Chen Y, Yang R, Qi B, Shan Z. Peptidogly-can-Chi3l1 interaction shapes gut microbiota in intestinal mucus layer. Elife. 2024 Oct 7;13:RP92994.
[37] Sipeki N., Kovats P.J., Deutschmann C., Schierack P., Roggenbuck D., Papp M. Loca-tion-based prediction model for Crohn’s disease regarding a novel serological marker, anti-chitinase 3-like 1 autoantibodies. World J. Gastroenterol. 2023; 29:5728–5750.
[38] Su PC, Chen CY, Yu MH, Kuo IY, Yang PS, Hsu CH, Hou YC, Hsieh HT, Chang CP, Shan YS, Wang YC. Fully human chitinase-3 like-1 monoclonal antibody inhibits tumor growth, fibrosis, angiogenesis, and immune cell remodeling in lung, pancreatic, and col-orectal cancers. Biomed Pharmacother. 2024 Jul; 176:116825.
[39] Wang S, Chen S, Jin M, et al. Diagnostic and prognostic value of serum Chitinase 3-like protein 1 in hepatocellular carcinoma. J Clin Lab Anal. 2022;36(2): e24234.
[40] Wang Z, Wang S, Jia Z, Hu Y, Cao D, Yang M, Liu L, Gao L, Qiu S, Yan W, Li Y, Luo J, Geng Y, Zhang J, Li Z, Wang X, Li M, Shao R, Liu Y. YKL-40 derived from infiltrating macrophages cooperates with GDF15 to es-tablish an immune suppressive microenvi-ronment in gallbladder cancer. Cancer Lett. 2023 Jun 1; 563:216184.
[41] Jin M, Liu H, Zheng Z, Fang S, Xi Y, Liu K. CHI3L1 mediates radiation resistance in col-orectal cancer by inhibiting ferroptosis via the p53/SLC7A11 pathway. J Transl Med. 2025;23(1):357.
[42] Díaz-Basabe A, Lattanzi G, Perillo F, Amo-roso C, Baeri A, Farini A, Torrente Y, Penna G, Rescigno M, Ghidini M, Cassinotti E, Baldari L, Boni L, Vecchi M, Caprioli F, Fac-ciotti F, Strati F. Porphyromonas gingi-valis fuels colorectal cancer through CHI3L1-mediated iNKT cell-driven immune evasion. Gut Microbes. 2024 Jan-Dec;16(1):2388801.
[43] Laucyte-Cibulskiene A., Ward L.J., Ebert T., Tosti G., Tucci C., Hernandez L., Kau-tzky-Willer A., Herrero M.T., Norris C.M., Pilote L., et al. Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: Focus on sex-specific associations with vascular outcomes and all-cause mor-tality. Biol. Sex Differ. 2021; 12:50.
[44] Wang C, Li K, Huang R, et al. Urine prote-omics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer. BMC Cancer. 2025;25(1):271.
[45] Wang B, Chen K, Gao M, et al. Chitinase 3-like 1 expression associated with lym-phatic metastasis and prognosis in urothelial carcinoma of the bladder. Clin Transl Im-munology. 2024;13(4): e1505.
[46] Chen T.K., Coca S.G., Thiessen-Philbrook H.R., Heerspink H.J.L., Obeid W., Ix J., Fried L., Bonventre J.V., El-Khoury J.M., Shlipak M.G., et al. Urinary biomarkers of tubular health and risk for kidney function decline or in diabetes. Am. J. Nephrol. 2023; 53:775–785.
[47] Zhang Y., Li T., Wang F., Liao C., Song S., Sun M., Zhang W. STAT3 contributes to wound healing in diabetic foot ulcer by tar-geting the CHI3L1/MAPK axis. J. Biol. Reg. Homeos. Ag. 2024; 38:2661–2672.
[48] Zhu Y, Chen JC, Zhang JL, Wang FF, Liu RP. A new mechanism of arterial calcification in diabetes: interaction between H3K18 lac-tylation and CHI3L1. Clin Sci (Lond). 2025 Jan 29;139(2):115-130.
[49] Chen Y.D., Huang C.Y., Wang Z.P., Wang W. Increased YKL-40 levels are linked with disease severity of initially diagnosed Graves’ disease. Libyan J. Med. 2023; 18:2212480.
[50] Ma Z, Wang G, Hu L. lncRNA EGFEM1P Drives the Progression of Papillary Thyroid Cancer by Regulating miR-6867-5p/CHI3L1 Axis. Crit Rev Eukaryot Gene Expr. 2023;33(6):29-41.
[51] Yu R, Liu X, Deng X, et al. Serum CHI3L1 as a biomarker of interstitial lung disease in rheumatoid arthritis. Front Immunol. 2023; 14:1211790.
[52] Tizaoui K, Yang JW, Lee KH, et al. The role of YKL-40 in the pathogenesis of autoim-mune diseases: a comprehensive review. Int J Biol Sci. 2022;18(9):3731-3746.
[53] Zou J, He X, Li W, et al. The association of serum CHI3L1 levels with the presence of Kawasaki disease. Sci Rep. 2025;15(1): 7693.
[54] Park KR, Park JI, Lee S, Yoo K, Kweon GR, Kwon IK, Yun HM, Hong JT. Chi3L1 is a therapeutic target in bone metabolism and a potential clinical marker in patients with os-teoporosis. Pharmacol Res. 2022 Oct; 184:106423.
[55] Xu W, Chao R, Xie X, Mao Y, Chen X, Chen X, Zhang S. IL13Rα2 as a crucial receptor for Chi3l1 in osteoclast differentiation and bone resorption through the MAPK/AKT pathway. Cell Commun Signal. 2024 Jan 30;22(1):81.
[56] Ji S, Yu H, Zhou D, Fan X, Duan Y, Tan Y, Lang M, Shao G. Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in tri-ple-negative breast cancer. J Transl Med. 2023 Oct 14;21(1):721.
[57] Wen YC, Lin CY, Ho KH, Lin YW, Hsiao CH, Wang SS, Chang LC, Yang SF, Chien MH. Functional variants of the chitinase 3-like 1 gene are associated with clinicopathologic outcomes and progression of prostate cancer. J Cell Mol Med. 2023 Dec;27(24):4202-4214.
[58] Zhao YH, Cai YX, Pan ZY, Tang F, Ma C, Wang ZF, Li G, Chang H, Tian SF, Li ZQ. Novel CHI3L1-Associated Angiogenic Phe-notypes Define Glioma Microenvironments: Insights From Multi-Omics Integration. Can-cer Sci. 2025 May;116(5):1433-1448.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Frontiers in Preventive Medicine